Alaric J. Dyckman received a B.S. degree in Chemistry from California State University, Chico, and a Ph.D. in Organic Chemistry from Stanford University, studying in the lab of Prof. Paul Wender. In 2000, he joined Bristol Myers Squibb as a medicinal chemist in the Immunoscience therapeutic area, initially working on a range of kinase targets, including TYK2, BTK and p38alpha, for which development compounds were identified. In addition, he has led programs for the treatment of autoimmune disorders. As the Chemistry lead for the S1P1 Agonist program, he oversaw the identification and advancement of several clinical development candidates, including BMS-986166 which entered clinical trials for Atopic Dermatitis. As the lead for Toll-like Receptor targeting programs, he helped to drive the identification of multiple development compounds, including BMS-986256, a potent and selective TLR7/8 dual antagonist under clinical evaluation for Systemic and Cutaneous Lupus Erythematosus.